FGFR aberrations increase the risk of brain metastases and predict poor prognosis in metastatic breast cancer patients

• Published in: Therapeutic advances in medical oncology 2020, Vol.12, p.1758835920915305-1758835920915305
• Main Authors: Xie, Ning, Tian, Can, Wu, Hui, Yang, Xiaohong, liu, Liping, Li, Jing, Xiao, Huawu, Gao, Jianxiang, Lu, Jun, Hu, Xuming, Cao, Min, Shui, Zhengrong, Tang, Yu, Wang, Xiao, Yang, Jianbo, Hu, Zhe-Yu, Ouyang, Quchang
• Format: Article
• Language: English
• Subjects: Brain cancer; Brain tumors; Breast cancer; Cancer therapies; Chemotherapy; ErbB-2 protein; Fibroblast growth factor receptor 1; Fibroblast growth factor receptors; Genetic screening; Immunohistochemistry; Medical prognosis; Metastases; Metastasis; Original Research; p53 Protein; Patients; Prognosis; Radiation therapy; Risk factors; Survival
• ISSN: 1758-8359; 1758-8340; 1758-8359
• DOI: 10.1177/1758835920915305

Background: The survival status of patients with breast cancer and brain metastasis (BCBM) receiving current treatments is poor. Method: We designed a real-world study to investigate using patients’ clinical and genetic aberrations to forecast the prognoses of BCBM patients. We recruited 146 BCBM patients and analyzed their clinical features to evaluate the overall survival (OS). For genetic testing, 30 BCBM and 165 non-brain-metastatic (BM) metastatic breast cancer (MBC) patients from Hunan Cancer Hospital, and 86 BCBM and 1416 non-BM MBC patients from the Geneplus database who received circulating tumor DNA testing, were compared and analyzed. Results: Ki67 >14% and >3 metastatic brain tumors were significant risk factors associated with poor OS, while chemotherapy and brain radiotherapy were beneficial factors for better OS. Compared with non-BM MBC patients, BCBM patients had more fibroblast growth factor receptor (FGFR) aberrations. The combination of FGFR, TP53 and FLT1 aberrations plus immunohistochemistry HER2-positive were associated with an increased risk of brain metastasis (AUC = 77.13%). FGFR aberration alone was not only a predictive factor (AUC = 67.90%), but also a significant risk factor for poor progression-free survival (Logrank p = 0.029). FGFR1 aberration was more frequent than other FGFR family genes in BCBM patients, and FGFR1 aberration was significantly higher in BCBM patients than non-BM MBC patients. Most FGFR1-amplified MBC patients progressed within 3 months of the late-line (>2 lines) treatment. Conclusion: A group of genetic events, including FGFR, TP53 and FLT1 genetic aberrations, and HER2-positivity, forecasted the occurrence of BM in breast cancers. FGFR genetic aberration alone predicted poor prognosis.